128 related articles for article (PubMed ID: 25931255)
1. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels.
Miura T; Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Takahashi H; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
Pancreas; 2015 Jul; 44(5):756-63. PubMed ID: 25931255
[TBL] [Abstract][Full Text] [Related]
2. Serum interleukin-6 levels reflect the disease status of colorectal cancer.
Chung YC; Chang YF
J Surg Oncol; 2003 Aug; 83(4):222-6. PubMed ID: 12884234
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Furuse J; Inagaki M; Higashi S; Kato H; Terao K; Ochiai A
Br J Cancer; 2013 May; 108(10):2063-9. PubMed ID: 23591198
[TBL] [Abstract][Full Text] [Related]
4. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment.
Cho HJ; Kim SS; Ahn SJ; Park SY; Park JH; Kim JK; Wang HJ; Cheong JY; Cho SW
Cytokine; 2015 Jun; 73(2):245-52. PubMed ID: 25797190
[TBL] [Abstract][Full Text] [Related]
5. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
Fahmueller YN; Nagel D; Hoffmann RT; Tatsch K; Jakobs T; Stieber P; Holdenrieder S
Int J Cancer; 2013 May; 132(10):2349-58. PubMed ID: 23047645
[TBL] [Abstract][Full Text] [Related]
8. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer.
Ramsey ML; Talbert E; Ahn D; Bekaii-Saab T; Badi N; Bloomston PM; Conwell DL; Cruz-Monserrate Z; Dillhoff M; Farren MR; Hinton A; Krishna SG; Lesinski GB; Mace T; Manilchuk A; Noonan A; Pawlik TM; Rajasekera PV; Schmidt C; Guttridge D; Hart PA
Pancreatology; 2019 Jan; 19(1):80-87. PubMed ID: 30497874
[TBL] [Abstract][Full Text] [Related]
9. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
Mitsunaga S; Ikeda M; Shimizu S; Ohno I; Takahashi H; Okuyama H; Ueno H; Morizane C; Kondo S; Sakamoto Y; Okusaka T; Ochiai A
Pancreas; 2016 Jan; 45(1):110-6. PubMed ID: 26566216
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern.
Kim HW; Lee JC; Paik KH; Kang J; Kim J; Hwang JH
Medicine (Baltimore); 2017 Feb; 96(5):e5926. PubMed ID: 28151872
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
12. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.
Wittwer C; Boeck S; Heinemann V; Haas M; Stieber P; Nagel D; Holdenrieder S
Int J Cancer; 2013 Dec; 133(11):2619-30. PubMed ID: 23729200
[TBL] [Abstract][Full Text] [Related]
13. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences.
Nakagawa H; Maeda S; Yoshida H; Tateishi R; Masuzaki R; Ohki T; Hayakawa Y; Kinoshita H; Yamakado M; Kato N; Shiina S; Omata M
Int J Cancer; 2009 Nov; 125(10):2264-9. PubMed ID: 19585572
[TBL] [Abstract][Full Text] [Related]
14. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Wereszczyńska-Siemiatkowska U; Kedra B; Lukaszewicz M; Baniukiewicz A; Szmitkowski M
Clin Chem Lab Med; 2008; 46(10):1423-8. PubMed ID: 18844497
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study.
de Raaf PJ; Sleijfer S; Lamers CH; Jager A; Gratama JW; van der Rijt CC
Cancer; 2012 Dec; 118(23):6005-11. PubMed ID: 22736424
[TBL] [Abstract][Full Text] [Related]
16. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.
Ebrahimi B; Tucker SL; Li D; Abbruzzese JL; Kurzrock R
Cancer; 2004 Dec; 101(12):2727-36. PubMed ID: 15526319
[TBL] [Abstract][Full Text] [Related]
17. Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancer.
Fogar P; Basso D; Pasquali C; Piva MG; Brigato L; De Paoli M; Galeotti F; Corsini A; Plebani M
Clin Chim Acta; 1998 Oct; 277(2):181-9. PubMed ID: 9853701
[TBL] [Abstract][Full Text] [Related]
18. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?
Scheede-Bergdahl C; Watt HL; Trutschnigg B; Kilgour RD; Haggarty A; Lucar E; Vigano A
Clin Nutr; 2012 Feb; 31(1):85-8. PubMed ID: 21855185
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer.
Feng L; Qi Q; Wang P; Chen H; Chen Z; Meng Z; Liu L
J Int Med Res; 2018 Dec; 46(12):5228-5236. PubMed ID: 30304975
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors.
Inagaki A; Ishida T; Ishii T; Komatsu H; Iida S; Ding J; Yonekura K; Takeuchi S; Takatsuka Y; Utsunomiya A; Ueda R
Int J Cancer; 2006 Jun; 118(12):3054-61. PubMed ID: 16425276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
